We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.52%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$449M
AUM Growth
+$34.2M
Cap. Flow
+$72.9M
Cap. Flow %
16.24%
Top 10 Hldgs %
46.73%
Holding
81
New
13
Increased
18
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
EXC icon
Exelon
EXC
+$28.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.85M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$9.77M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$9.45M
5
ONC
BeOne Medicines Ltd
ONC
+$6.75M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.1M
2
EXEL icon
Exelixis
EXEL
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$8.27M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.64M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 97.78%
2 Utilities 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
76
DELISTED
bluebird bio
BLUE
– –
-849
Closed -$210K
ENTA icon
77
Enanta Pharmaceuticals
ENTA
$402M
– –
-40,000
Closed -$2.26M
ESPR
78
DELISTED
Esperion Therapeutics
ESPR
– –
-9,500
Closed -$114K
EXEL icon
79
Exelixis
EXEL
$13.7B
– –
-489,534
Closed -$10.3M
KYNB
80
Kyntra Bio
KYNB
$32.4M
– –
-788
Closed -$201K
DCPH
81
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-16,600
Closed -$564K
1 2 3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2021 Portfolio in Review

As of Q4 2021, International Biotechnology Trust held 81 positions worth $449M, up 8.3% from $415M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust deployed $72.9M of net new capital in Q4 2021, opening 13 new positions and adding to 18 existing holdings. Its largest new stake was Exelon: 766,241 shares worth $9.98M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Utilities.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $15.1M trimmed.

  • International Biotechnology Trust's largest Q4 2021 buy was Exelon: 766,241 shares worth $9.98M.
  • International Biotechnology Trust added most to Alnylam Pharmaceuticals in Q4 2021, an estimated $9.85M increase.
  • International Biotechnology Trust's biggest Q4 2021 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $15.1M.
  • International Biotechnology Trust fully exited Exelixis in Q4 2021, selling an estimated $10.3M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $449M portfolio in Q4 2021.
  • International Biotechnology Trust opened 13 new positions and closed 8 in Q4 2021.
  • International Biotechnology Trust's portfolio value rose 8.3% quarter-over-quarter to $449M.

Based on International Biotechnology Trust's 13F filing for Q4 2021, filed 15 Feb 2022.